
HSCS Stock Forecast & Price Target
HSCS Analyst Ratings
Bulls say
HeartSciences Inc. has updated its FY26 earnings per share (EPS) estimates positively, reflecting an upward adjustment to $(3.76) from a previous $(4.17), indicating improved financial projections and a growing confidence in its market potential. The anticipated approval of the MyoVista device, alongside the rollout of the MyoVista Insights cloud platform and expected FDA approval of its diagnostic algorithm by the first half of 2026, positions the company well for significant growth in the healthcare sector. With a newly established price target of $9.20, which suggests substantial upside potential, HeartSciences is strategically poised to tap into a large market opportunity in cardiac diagnostics.
Bears say
HeartSciences Inc. is facing significant financial challenges, as evidenced by a sharp reduction in projected FY2026 revenue estimates, which have been lowered from $1.2 million to $0.1 million due to FDA-related delays. Moreover, the company is encountering multiple risks that could adversely affect its financial performance, including balance sheet and liquidity issues, potential failure of product candidates in clinical trials, and challenges in securing regulatory approvals and reimbursement. The overall outlook is further complicated by competition and changing macroeconomic conditions, which could diminish investor sentiment towards healthcare stocks, thereby impacting the company's financial viability.
This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.
HSCS Analyst Forecast & Price Prediction
Start investing in HSCS
Order type
Buy in
Order amount
Est. shares
0 shares